TNF and psoriasis: In recent years, the management of moderate-to-severe psoriasis has been revolutionized by the introduction of biologic therapies targeting specific cytokines implicated in disease pathogenesis, including tumor necrosis factor alpha (TNF-α), interleukin-12/23 (IL-12/23), IL-17, and IL-23 [6,7].